Bentley Pharmaceuticals Inc.

bentley pharmaceuticals inc. - All News and Analysis

• Generic Drugs: Industry Snapshot

  Seeking Alpha - 2008-08-15

  Mike Havrilla submits:Global Generic Drug Industry: Benchmark Comps  Global Generic Drug Industry: Top 5 Companies by Market Cap Global Generic Drugs: Top 5 Companies by Stock Performance  The accompanying tables provide a snapshot of my 38-company Global Generic Drug Index, which is rapidly consolidating amidst a flurry of recent M&A activity --...

  Tags: Healthcare, Bentley Pharmaceuticals Inc., Barr Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Sanofi-Aventis

• Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock

  - 2008-07-08

  EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT) ("Bentley" or the "Company") announced today that it notified the New York Stock Exchange (the "NYSE") of its intent to delist its common stock, par value $0.02 per share, from the NYSE immediately following the consummation of the transactions contemplated by the...

  Tags: Bentley, Bentley Pharmaceuticals Inc., Company, FINANCE, Investment, merger, New York Stock Exchange, SEC, Teva

• Bentley Pharmaceuticals & Teva Pharmaceutical Industries Ltd. Merger Consideration Established at $14.82 Per Share

  - 2008-07-03

  EXETER, N.H. -- Bentley Pharmaceuticals, Inc. ("Bentley") (NYSE: BNT) announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd. ("Teva") has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, CPEX Pharmaceuticals, Inc....

  Tags: Bentley, Bentley Pharmaceuticals Inc., FINANCE, Investment, merger, SEC, Teva

• Bentley Board Approves Spin-off of Drug Delivery Business

  - 2008-06-12

  Bentley Sets July 22, 2008 as Date for Stockholders to Vote on Proposed Acquisition by Teva Pharmaceutical Industries Ltd. EXETER, N.H. -- The board of directors of Bentley Pharmaceuticals, Inc. (NYSE: BNT) today approved the spin-off of its drug delivery business into a new publicly traded company to be...

  Tags: Bentley, Bentley Pharmaceuticals Inc., board, FINANCE, Investment, merger, SEC

• Bentley Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-27

  Question-and-Answer SessionOperator Operator Instruction Your first question comes from Randall Stanicky of Goldman Sachs. Randall Stanicky - Goldman Sachs Hey, guys. Thanks a lot for the question and again congratulations on getting the deal with Teva in place. I just have one question and John I was hoping...

  Tags: Bentley Pharmaceuticals Inc.

• Bentley Pharmaceuticals Announces First Quarter Financial Results

  - 2008-05-08

  Reports Revenues of $40.0 Million in the First Quarter; Revenues Increase 27% over 2007 First Quarter EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today reported financial results for the first quarter and three months ended March 31, 2008. First quarter 2008 revenues...

  Tags: Bentley Pharmaceuticals Inc., Company, EBITDA, FINANCE, financial, GAAP, Investment, merger, revenue, SEC

• Teva to Acquire Bentley Pharmaceuticals

  - 2008-03-31

  Acquisition Will Provide Teva with a Strong Platform to Become a Leading Player in Spain JERUSALEM & EXETER, N.H. -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Bentley Pharmaceuticals, Inc. (NYSE: BNT) announced today that they have entered into a definitive agreement under which Teva will acquire Bentley. The...

  Tags: acquisition, Bentley Pharmaceuticals Inc., SEC, shareholder, Teva

• Bentley Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-03-13

  Question-and-Answer SessionOperator Thank you. Operator Instructions. Your first question is from David Merris with Balyasny. Please go ahead. David Merris Good morning guys. Question on the strategic options on the generic business without going in to any details, I am sure you wouldn’t – what’s...

  Tags: Bentley Pharmaceuticals Inc.

• Auxilium Pharmaceuticals, Inc. and Bentley Pharmaceuticals, Inc. Announce Issuance of Patent Covering Testim(R)

  - 2008-01-22

  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Bentley Pharmaceuticals, Inc. (NYSE: BNT) today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 7,320,968 covering Testim®, 1% testosterone gel, marketed by Auxilium under license from Bentley. The patent will expire in January 2025. ...

  Tags: Auxilium Pharmaceuticals Inc., Bentley Pharmaceuticals Inc., Company, patent, SEC

• Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Presenter Profiles

  - 2006-05-12

  MONTE CARLO, Monaco -- Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 takes place May 15-16 in Monte Carlo. For in-depth information about the event visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf9. Below are profiles from Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 presenters; breaking news releases are available at...

  Tags: AMEX, Arbios Systems Inc., Bentley Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., biotechnology, Ceragenix Pharmaceuticals Inc., Company, compound, Cyclacel Pharmaceuticals Inc., Cytogen Corp., CytRx Corp., Dyadic International Inc., EntreMed Inc., GammaCan International Inc., Genta Inc., Insmed Inc., Inyx Inc., Medivation Inc., Nasdaq Stock Market Inc., Parkinson, patient, phone, Provectus Pharmaceuticals Inc., technology, therapy, ticker, Web

• Roth Capital Partners 18th Annual Growth Stock Conference Presenter Profiles

  - 2006-02-17

  DANA POINT, Calif. -- Roth Capital Partners 18th Annual Growth Stock Conference takes place Feb. 20-22 at the St. Regis Monarch Beach Resort & Spa in Dana Point, Calif. For in-depth information about the event visit http://www.rothcp.com/index06%20DP.html. Below are profiles from Roth Capital Partners 18th Annual Growth Stock Conference...

  Tags: Amerigon Inc., AMEX, Annual, Antares Pharma Inc., AspenBio Pharma Inc., AXT Inc., Bentley Pharmaceuticals Inc., Bodisen Biotech Inc., California, Clarient Inc., CollaGenex Pharmaceuticals Inc., Company, Delta Financial Corp., Diomed Holdings Inc., Emrise Corp., GeoPharma Inc., manufacturing, MedicalCV Inc., Merit Medical Systems Inc., Middleby Corp., MPA, Nasdaq Stock Market Inc., Neogen Corp., NetScout Systems Inc., network, Peregrine Pharmaceuticals Inc., stock, technology, Web, Zi Corp.

• Roth Capital Partners New York Conference 2005 Presenter Profiles

  - 2005-09-06

  NEW YORK -- The Roth Capital Partners New York Conference takes place Sept. 7-8 at The Westin New York at Times Square. For in-depth information about the event visit http://www.rothcp.com/. Below are profiles from Roth Capital Partners New York Conference exhibitors; breaking news releases are available at http://www.tradeshownews.com, Business...

  Tags: Airspan Networks Inc., Amerigon Inc., Amerityre Corp., Amex, Authentidate Holding Corp., Bentley Pharmaceuticals Inc., BioSphere Medical Inc., brand, Buckle Inc., Clarient Inc., Company, Concurrent Computer Corp., Delta Financial Corp., Dyadic International Inc., Fusion, I-Flow Corp., LivePerson Inc., Middleby Corp., Nasdaq Stock Market Inc., Neogen Corp., network, Newtek Business Services Inc., Orthovita Inc., Oxigene Inc., patient, phone, Pro-Dex Inc., Prospect Medical Holdings Inc., Psychemedics Corp., Radyne Corp., technology, Web

• Bentley Pharmaceuticals, Inc. to Present Results of Initial Phase II Intranasal Insulin Study; Bentley Will Present Findings at the American Diabetes Association 65th Scientific Sessions, June 10-14, 2005

  - 2005-04-21

  EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe (the "Company"), today announced that it has recently completed its data analysis of its Phase II clinical trial in Ireland of its proprietary intranasal...

  Tags: American Diabetes Association, Bentley Pharmaceuticals Inc.

• Bentley Pharmaceuticals to Present At UBS Warburg Conference

  - 2002-05-30

  Business Editors NORTH HAMPTON, N.H.--BUSINESS WIRE--May 30, 2002 Bentley Pharmaceuticals, Inc. (AMEX: BNT) a specialty pharmaceutical company focused on advanced drug-delivery technologies, which also manufactures and markets generic and branded products in Europe, today announced that James R. Murphy, chairman and CEO, will be speaking at the UBS...

  Tags: Bentley Pharmaceuticals Inc., UBS Warburg

Additional Resources

• CPEX Pharmaceuticals Reports Third-Quarter 2008 Financial Results

  - 2008-11-06

  EXETER, N.H. -- CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today reported financial results for the third quarter ended September 30, 2008. The Company reported revenues of $3.9 million and a net loss of $1.0 million for the three months ended September 30, 2008. CPEX began operating as an independent...

• CPEX Pharmaceuticals Reports Second-Quarter 2008 Financial Results

  - 2008-08-14

  EXETER, N.H. -- CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today reported revenues of $3.9 million and a net loss of $1.7 million for the second quarter ended June 30, 2008, compared to revenues of $2.7 million and a net loss of $1.8 million in the same period of the prior year....

• Teva Completes Acquisition of Bentley Pharmaceuticals

  - 2008-07-23

  -Teva Gains a Strong Platform to Become a Leading Player in Spain- JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has completed its acquisition of Bentley Pharmaceuticals, Inc. (NYSE: BNT), which will operate in Spain under the Teva name. At closing, Bentley consisted solely...

• Bentley Pharmaceuticals' Stockholders Approve Merger Agreement

  - 2008-07-22

  Acquisition by Teva Pharmaceutical Industries Ltd. is Complete EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT) ("Bentley" or the "Company") announced today that its stockholders have approved the Agreement and Plan of Merger, dated as of March 31, 2008, by and among the Company, Teva Pharmaceutical Industries Ltd....

• Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock

  - 2008-07-08

  EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT) ("Bentley" or the "Company") announced today that it notified the New York Stock Exchange (the "NYSE") of its intent to delist its common stock, par value $0.02 per share, from the NYSE immediately following the consummation of the transactions contemplated by the...

• Bentley Pharmaceuticals & Teva Pharmaceutical Industries Ltd. Merger Consideration Established at $14.82 Per Share

  - 2008-07-03

  EXETER, N.H. -- Bentley Pharmaceuticals, Inc. ("Bentley") (NYSE: BNT) announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd. ("Teva") has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, CPEX Pharmaceuticals, Inc....

• Incorporated: 1974
• CEO: Mr. James R. Murphy